RT Journal Article
SR Electronic
T1 Measuring Subjective Cognitive Decline in Older Adults: Harmonization between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.27.21262840
DO 10.1101/2021.09.27.21262840
A1 Wells, Lindsey F
A1 Risacher, Shannon L
A1 McDonald, Brenna C
A1 Farlow, Martin R
A1 Brosch, Jared
A1 Gao, Sujuan
A1 Apostolova, Liana G
A1 Saykin, Andrew J
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/29/2021.09.27.21262840.abstract
AB Background Self and informant (proxy or study partner) reports of everyday cognitive functioning have been shown to be associated with incipient neurodegenerative disease. The 20-item Cognitive Change Index (CCI) and the 39-item Measurement of Everyday Cognition (ECog) were each developed to characterize early subjective changes in cognitive function.Objective We examined the relationship between CCI and ECog self and informant evaluations to determine content overlap and provide a co-calibration for converting between these widely used instruments.Methods 950 participants (57.1% female, mean age=71.2yrs) from ADNI and the Indiana ADRC with self evaluations and 279 participants (60.9% female, mean age=71.8yrs) with informant evaluations (Indiana ADRC) were included. Analyzed variables for the CCI and ECog included domain mean scores, memory domain total scores, and total scores for all items. Pearson correlations, regression analyses, and frequency distributions were used to assess the relationship between CCI and ECog. Sex, years of education, race, APOE ε4 carrier status, and baseline diagnosis were also analyzed as potentially relevant covariates.Results CCI and ECog total scores were highly correlated for the self (r=0.790, p<0.001) and informant (r=0.860, p<0.001) versions. Frequency distributions of total scores were generated and self and informant histograms were plotted separately. Quadratic regressions for self (r2=0.682) and informant (r2=0.863) scores were used to create a translation table between the CCI and ECog total scores.Conclusion Self and informant total scores can be harmonized and translated between the CCI and ECog to facilitate cross-study and longitudinal assessment of perceived cognitive change, an important patient-reported outcome.Competing Interest StatementDr. Farlow receives support from Avanir (AVP-923), Biogen (BIIB037), Cognition Therapeutics (CT1812), Eli Lilly and Company (LY450139), Green Valley, Otsuka (OPC-34712), Neurotrope Biosciences, AZTherapies, Athira, Ionis and Lexeo. He also serves on the Oligomerik Advisory Board and the T3D Advisory Board. Dr. Brosch receives support from the following industry sponsors: AbbVie, Athira, Eisai America, Eli Lilly, Green Valley Pharmaceuticals and Takeda. He also receives support from Washington University, UCSD, Biohaven, USC and Boston University. Dr. Gao receives support from multiple NIH grants to Indiana University (P30 AG010133, P30 AG072976, R01HL131730, R01AG052493, R01AG055391, R01AG057733, R01AG061452, R01AG067631, U01AG057195, R01NR018162) and a grant from Indiana State Department of Health to Indiana University (Project Number: 0000000000000055059). Dr. Apostolova receives support from multiple grants (NIA U01 AG057195; NIA R01 AG057739; NIA P30 AG010133; Alzheimer Association LEADS GENETICS 19-639372; Roche Diagnostics RD005665). She has previously consulted for Eli Lilly, Biogen and Two Labs. She received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AAN, Mayo clinic, Purdue university, Biogen, MillerMed, APha, and MJH Holdings LLC. She also receives support from the Data Safety Monitoring Board (NIH R01 grant and IQVIA). Dr. Saykin receives support from multiple NIH grants to Indiana University (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, U01 AG068057 and U01 AG072177). IU has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor). Dr. Saykin served on a Bayer Oncology Scientific Advisory Board and Siemens Medical Solutions USA, Inc. Dementia Advisory Board. He reports support from Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior).Funding StatementDr. Farlow receives support from Avanir (AVP-923), Biogen (BIIB037), Cognition Therapeutics (CT1812), Eli Lilly and Company (LY450139), Green Valley, Otsuka (OPC-34712), Neurotrope Biosciences, AZTherapies, Athira, Ionis and Lexeo. He also serves on the Oligomerik Advisory Board and the T3D Advisory Board. Dr. Brosch receives support from the following industry sponsors: AbbVie, Athira, Eisai America, Eli Lilly, Green Valley Pharmaceuticals and Takeda. He also receives support from Washington University, UCSD, Biohaven, USC and Boston University. Dr. Gao receives support from multiple NIH grants to Indiana University (P30 AG010133, P30 AG072976, R01HL131730, R01AG052493, R01AG055391, R01AG057733, R01AG061452, R01AG067631, U01AG057195, R01NR018162) and a grant from Indiana State Department of Health to Indiana University (Project Number: 0000000000000055059). Dr. Apostolova receives support from multiple grants (NIA U01 AG057195; NIA R01 AG057739; NIA P30 AG010133; Alzheimer Association LEADS GENETICS 19-639372; Roche Diagnostics RD005665). She has previously consulted for Eli Lilly, Biogen and Two Labs. She received honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AAN, Mayo clinic, Purdue university, Biogen, MillerMed, APha, and MJH Holdings LLC. She also receives support from the Data Safety Monitoring Board (NIH R01 grant and IQVIA). Dr. Saykin receives support from multiple NIH grants to Indiana University (P30 AG010133, P30 AG072976, R01 AG019771, R01 AG057739, U01 AG024904, R01 LM013463, R01 AG068193, T32 AG071444, U01 AG068057 and U01 AG072177). IU has also received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor). Dr. Saykin served on a Bayer Oncology Scientific Advisory Board and Siemens Medical Solutions USA, Inc. Dementia Advisory Board. He reports support from Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. This study was approved by the Indiana University (IU) Institutional Review Board for data access and analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI; http://adni.loni.usc.edu) and the Indiana Alzheimer's Disease Research Center (IADRC) including participants from the Indiana Aging and Memory Study (IMAS) initial phase and IADRC phases.